SecBot SecBot
PRESS-RELEASE ·Filed Jun 9, 2026

IRON

Disc Medicine Inc
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

APOLLO readout in Q4 2026 is the next major catalyst; monitor for enrollment updates or interim analysis. Positive data would likely drive significant upside; failure would be severely negative. Consider positioning ahead of APOLLO results.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$68.34
T+0 close · Jun 9, 2026 · via day close
Latest settled
+17.13%
T+60 · $80.05
Vs SPY
+13.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 9 $68.34entry
  2. T+1 · 5mo ago −1.59%α −0.02% · $67.25
  3. T+5 · 5mo ago +2.56%α +0.15% · $70.09
  4. T+20 · 4mo ago +16.71%α +15.26% · $79.76
  5. T+60 · 3mo ago +17.13%α +13.32% · $80.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for responding to the CRL for bitopertin in EPP and potentially support traditional approval. This provides a clearer path forward after the CRL, reducing regulatory uncertainty. APOLLO data is expected in Q4 2026, with an FDA decision by mid-2027.

Key Facts

  • FDA aligned that successful Phase 3 APOLLO study can support CRL response and potentially traditional approval.
  • APOLLO data expected in Q4 2026; CRL response submission by end of 2026.
  • FDA decision on bitopertin expected by mid-2027.
  • Bitopertin is a potential first disease-modifying therapy for EPP.

Financial Impact

Reduced regulatory risk; potential for approval by mid-2027 could unlock significant revenue for bitopertin in EPP.

probability of approvalfuture revenue outlook

Risk Factors

  • APOLLO may fail to meet endpoints, leading to approval delay or denial.
  • Competition from other EPP treatments or alternative therapies.
  • Regulatory setbacks or additional CRL items

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3308825

Track record

43 reports on IRON

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026